Clinical Trial: AG Plus Nimotuzumab Sequential Irreversible Electroporation Ablation for Locally Advanced Pancreatic Cancer

U.S., April 23 -- ClinicalTrials.gov registry received information related to the study (NCT06938503) titled 'AG Plus Nimotuzumab Sequential Irreversible Electroporation Ablation for Locally Advanced Pancreatic Cancer' on April 14.

Brief Summary: This is a prospective, open-label, single arm clinical study. The main purpose of the study is to evaluate the clinical efficacy and safety of nab-paclitaxel/gemcitabine combined with nimotuzumab sequential irreversible electroporation ablation for locally advanced pancreatic cancer. The main endpoint is overall survival (OS).

Study Start Date: April 21

Study Type: INTERVENTIONAL

Condition: Pancreatic Cancer, Adult

Intervention: DRUG: AG regimen

Patients will receive 4 cycles of AG (gemcita...